Navigation Links
Epizyme to Partner to Develop DOT1L Companion Diagnostic

CAMBRIDGE, Mass., April 18, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has signed an agreement with Abbott, a global healthcare company, to develop a molecular companion diagnostic test for use with EPZ-5676. EPZ-5676, Epizyme's most advanced clinical product candidate, is an inhibitor targeting the DOT1L histone methyltransferase (HMT) for the treatment of mixed lineage leukemia (MLL-r), an aggressive genetically defined subtype of the two most common forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Under the agreement, Abbott will utilize its proprietary fluorescence in situ hybridization (FISH) technology to design a test to detect MLL genetic alterations that lead to the oncogenic (cancer causing) function of DOT1L. Epizyme will use Abbott's FISH-based test to help identify eligible patients for its DOT1L inhibitor.

About mixed lineage leukemia (MLL-r)
MLL-r is an aggressive subtype of two of the most common forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), caused by a chromosomal translocation involving the MLL gene. Based on published research, the five-year overall survival rate for adult patients with the MLL-r subtype of AML ranges from approximately 5 to 24 percent. MLL-r occurs in both an adult population and an infant/pediatric population. At this time, there are no approved therapies specifically indicated for MLL-r.

About Epizyme, Inc.
Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). To date, Epizyme has entered into therapeutic collaborations with Celgene, Eisai and GSK that have provided it with approximately $120 million in non-equity funding through December 31, 2012. 

For more information, visit and connect with us on Twitter at @EpizymeRx.

SOURCE Epizyme
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epizyme to Present at Upcoming Conferences in February
2. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
3. Tria Beauty, Inc. and Ulta Announce New Retail Partnership
4. Richard Atkin to Join MedTech Nordic Investing & Partnering 2013
5. RoundTable Healthcare Partners and Argon Medical Devices Complete Acquisition of Angiotech Pharmaceuticals Interventional Products Business
6. Profil Institute and Mercodia Announce Partnership Offering Insulin and Metabolism ELISA Assays to Enhance Diabetes and Obesity Clinical Trials
7. Core Informatics and OpenEye Scientific Software Forge Partnership
8. Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs
9. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
10. GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive Today
11. GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive
Post Your Comments:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
Breaking Medicine News(10 mins):